Boosted by a recent €12m cash injection from leading healthcare investor Sofinnova Partners, France's Abivax can now focus on steering its flagship anti-inflammatory ABX464 through three key mid-stage trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?